Episode 393: Antibody–Drug Conjugates in Metastatic Breast Cancer
From The ONS Podcast · · 20 min
This plays from the publisher's own server. We do not host a copy.
Description
"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer.
Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.
Episode Notes
- This episode is not eligible for NCPD.
- ONS Podcast™ episodes: - Episode 391: Pharmacology 101: Antibody–Drug Conjugates
- Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer
- Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer
- Episode 350: Breast Cancer Treatment Considerations for Nurses
- Episode 303: Cancer Symptom Management Basics: Ocular Toxicities
- ONS Voice articles: - An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities
- Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options
- Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer
- What Is HER2-Low Breast Cancer?
- ONS Voice drug reference sheets: - Belantamab mafodotin-blmf
- Datopotamab deruxtecan-dlnk
- Enfortumab vedotin-ejfv
- Fam-trastuzumab deruxtecan-nxki
- ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)
- Guide to Breast Care for Oncology Nurses
- Guide to Cancer Immunotherapy (second edition)
- ONS courses: - ONS Fundamentals of Chemotherapy and Immunotherapy Administration™
- ONS/ONCC® Chemotherapy Immunotherapy Certificate™
- Clinical Journal of Oncology Nursing article: - Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care
- The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer
- Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes
- ONS huddle cards: - Altered Body Image Huddle Card
- Chemotherapy Huddle Card
- Targeted Therapy Huddle Card
- Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study
- ONS Biomarker Database (https://www.ons.org/clinical-tools/biomarkers) (refine by breast cancer)
- ONS Breast Cancer Learning Library
- American Society of Clinical Oncology (https://www.asco.org/) (ASCO) homepage
- Drugs@FDA package inserts
- National Comprehensive Cancer Network homepage (https://www.nccn.org/)
- Susan G. Komen metastatic breast cancer page (https://www.komen.org/breast-cancer/metastatic/)
To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/).
To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Highlights From This Episode
"What an ADC is doing is taking the antibody and linking it to a…